OTCMKTS:NVZMY - NOVOZYMES A/S/S Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$47.4750 -0.27 (-0.57 %)
(As of 03/25/2019 04:00 PM ET)
Previous Close$47.75
Today's Range$47.11 - $47.64
52-Week Range$40.38 - $55.84
Volume8,742 shs
Average Volume42,952 shs
Market Capitalization$14.10 billion
P/E Ratio27.13
Dividend Yield1.05%
Beta0.84
Novozymes A/S produces and sells industrial enzymes and microorganisms worldwide. The company offers agriculture solutions, including crop protection, and animal health and nutrition solutions; fermentation, lignecellulosic hydrolysis, liquefaction, process enhancement, and saccharifaction solutions for bioenergy; baking, beverages, dairy, and protein ingredients for the food and beverage industry; and laundry, dishwashing, hand washing, and cleaning solutions for the household care industry. It also provides wastewater solutions, such as additives, biogas production, industrial bio cleaning, compound removal, odor control, and system start-up solutions; and textile solutions comprising bioscouring, bleach clean-up, desizing, denim finishing and abrasion, and biopolishing solutions. In addition, the company offers forest products that include bleach boosting, deinking, fiber modification, effluent control, pitch and stickies control, and starch modification products; and leather solutions, which comprise biopreparation, degreasing, and re-bating. Further, it provides pharmaceutical solutions, including lipases, immobilized lipases, and proteases for biocatalysis; and rtrypsin for cell culture. Novozymes A/S has a strategic collaboration with Boehringer Ingelheim Animal Health for the research and development, production, marketing, and sale of a portfolio of probiotic products. The company was founded in 1925 and is headquartered in Bagsvaerd, Denmark.

Receive NVZMY News and Ratings via Email

Sign-up to receive the latest news and ratings for NVZMY and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorBasic Materials
Current SymbolOTCMKTS:NVZMY
CUSIPN/A
CIKN/A
Phone45-4446-0000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.28 billion
Cash Flow$1.8743 per share
Book Value$6.81 per share

Profitability

Net Income$511.29 million

Miscellaneous

Employees6,245
Market Cap$14.10 billion
Next Earnings Date4/24/2019 (Estimated)
OptionableNot Optionable

NOVOZYMES A/S/S (OTCMKTS:NVZMY) Frequently Asked Questions

What is NOVOZYMES A/S/S's stock symbol?

NOVOZYMES A/S/S trades on the OTCMKTS under the ticker symbol "NVZMY."

How often does NOVOZYMES A/S/S pay dividends? What is the dividend yield for NOVOZYMES A/S/S?

NOVOZYMES A/S/S announced an annual dividend on Thursday, February 7th. Stockholders of record on Friday, March 1st will be paid a dividend of $0.504 per share on Tuesday, March 19th. This represents a dividend yield of 1.16%. The ex-dividend date is Thursday, February 28th. View NOVOZYMES A/S/S's Dividend History.

How were NOVOZYMES A/S/S's earnings last quarter?

NOVOZYMES A/S/S (OTCMKTS:NVZMY) released its quarterly earnings data on Thursday, January, 24th. The biotechnology company reported $0.44 EPS for the quarter, beating the consensus estimate of $0.42 by $0.02. The biotechnology company earned $567.89 million during the quarter. NOVOZYMES A/S/S had a return on equity of 29.64% and a net margin of 22.14%. View NOVOZYMES A/S/S's Earnings History.

When is NOVOZYMES A/S/S's next earnings date?

NOVOZYMES A/S/S is scheduled to release their next quarterly earnings announcement on Wednesday, April 24th 2019. View Earnings Estimates for NOVOZYMES A/S/S.

What is the consensus analysts' recommendation for NOVOZYMES A/S/S?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NOVOZYMES A/S/S in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for NOVOZYMES A/S/S.

Has NOVOZYMES A/S/S been receiving favorable news coverage?

Media coverage about NVZMY stock has been trending somewhat negative on Monday, according to InfoTrie. The research group identifies positive and negative news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. NOVOZYMES A/S/S earned a news sentiment score of -1.1 on InfoTrie's scale. They also assigned news articles about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the immediate future.

Who are some of NOVOZYMES A/S/S's key competitors?

What other stocks do shareholders of NOVOZYMES A/S/S own?

Who are NOVOZYMES A/S/S's key executives?

NOVOZYMES A/S/S's management team includes the folowing people:
  • Mr. Peder Holk Nielsen, Pres & CEO (Age 63)
  • Dr. Prisca Havranek-Kosicek, CFO & Exec. VP of Corp. Functions (Age 44)
  • Mr. Thomas Videbaek, Exectuive VP & COO of Research, Innovation & Supply (Age 59)
  • Mr. Andrew Fordyce, Exec. VP of Food & Beverages (Age 56)
  • Mr. Anders Lund, Exec. VP of Household Care & Technical Industries (Age 46)

How do I buy shares of NOVOZYMES A/S/S?

Shares of NVZMY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is NOVOZYMES A/S/S's stock price today?

One share of NVZMY stock can currently be purchased for approximately $47.4750.

How big of a company is NOVOZYMES A/S/S?

NOVOZYMES A/S/S has a market capitalization of $14.10 billion and generates $2.28 billion in revenue each year. The biotechnology company earns $511.29 million in net income (profit) each year or $1.75 on an earnings per share basis. NOVOZYMES A/S/S employs 6,245 workers across the globe.

What is NOVOZYMES A/S/S's official website?

The official website for NOVOZYMES A/S/S is http://www.novozymes.com.

How can I contact NOVOZYMES A/S/S?

NOVOZYMES A/S/S's mailing address is Krogshoejvej 36, Bagsvaerd G7, 2880. The biotechnology company can be reached via phone at 45-4446-0000 or via email at [email protected]


MarketBeat Community Rating for NOVOZYMES A/S/S (OTCMKTS NVZMY)

Community Ranking:  1.6 out of 5 (star)
Outperform Votes:  74 (Vote Outperform)
Underperform Votes:  154 (Vote Underperform)
Total Votes:  228
MarketBeat's community ratings are surveys of what our community members think about NOVOZYMES A/S/S and other stocks. Vote "Outperform" if you believe NVZMY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVZMY will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/25/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel